Advertisement

Topics

Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease

13:22 EDT 14 Jun 2019 | Xconomy

[Updated 3:19 p.m.] The latest price tag for a gene therapy, a treatment meant to provide a long-lasting effect with a single dose, is now set. The treatment, Zynteglo, developed for the rare blood disease beta thalassemia, will cost roughly $1.8 million. Bluebird Bio (NASDAQ: BLUE), which just won approval of Zynteglo in Europe two […]

Original Article: Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease

NEXT ARTICLE

More From BioPortfolio on "Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...